SOPH
$5.00
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic mod...
Recent News
Sophia Genetics SA (SOPH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Sophia Genetics SA (SOPH) reports a 22% increase in Q4 revenue, expands customer base, and outlines strategic growth plans for 2026.
SOPHiA GENETICS Q4 Earnings Call Highlights
SOPHiA GENETICS (NASDAQ:SOPH) executives highlighted accelerating commercial momentum, expanding platform capabilities, and improved profitability outlook during the company’s fourth-quarter and full-year 2025 earnings call. Management also discussed leadership changes, major customer wins, and prog
SOPHiA GENETICS S.A. Q4 2025 Earnings Call Summary
Moby summary of SOPHiA GENETICS S.A.'s Q4 2025 earnings call
SOPHiA GENETICS (SOPH) Q4 2025 Earnings Transcript
In Q3, these efforts continued to pay off as revenue growth accelerated for a third consecutive quarter. Given the strong performance and the accelerating momentum we are seeing across the business, we are raising our 2025 revenue guidance to $75 million to $77 million. Starting with the first growth driver, in Q3, we signed 31 new customers.
Why The SOPHiA GENETICS (SOPH) Narrative Is Shifting On Richer Valuation And Growth Expectations
Analysts have lifted their price target for SOPHiA GENETICS by $1, signalling a slightly higher view of what the shares could reasonably be worth. That move is grounded in updated models, where more optimistic voices see enough support to justify the extra $1, while cautious analysts question how much cushion it really provides. As you read on, you will see how this evolving narrative might shape the way you track the stock from here. Analyst Price Targets don't always capture the full story...